Porth Ymchwil

Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

StandardStandard

Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. / Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F. et al.
Yn: The Lancet, Cyfrol 369, Rhif 9561, 01.02.2007, t. 559-570.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

HarvardHarvard

Coombes, RC, Kilburn, LS, Snowdon, CF, Paridaens, R, Coleman, RE, Jones, SE, Jassem, J, Van de Velde, CJ, Delozier, T, Alvarez, I, Del Mastro, L, Ortmann, O, Diedrich, K, Coates, AS, Bajetta, E, Holmberg, SB, Dodwell, D, Mickiewicz, E, Andersen, J, Lonning, PE, Coccini, G, Forbes, J, Castiglione, M, Stuart, NS, Stewart, A, Fallowfield, LJ, Bertelli, G, Hall, E, Bogle, RG, Carpentieri, M, Colajori, E, Subar, M, Ireland, E & Bliss, JM 2007, 'Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.', The Lancet, cyfrol. 369, rhif 9561, tt. 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1

APA

Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., Jassem, J., Van de Velde, C. J., Delozier, T., Alvarez, I., Del Mastro, L., Ortmann, O., Diedrich, K., Coates, A. S., Bajetta, E., Holmberg, S. B., Dodwell, D., Mickiewicz, E., Andersen, J., ... Bliss, J. M. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet, 369(9561), 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1

CBE

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, et al. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 369(9561):559-570. https://doi.org/10.1016/S0140-6736(07)60200-1

MLA

Coombes, R.C. et al. "Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.". The Lancet. 2007, 369(9561). 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1

VancouverVancouver

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 2007 Chw 1;369(9561):559-570. doi: 10.1016/S0140-6736(07)60200-1

Author

Coombes, R.C. ; Kilburn, L.S. ; Snowdon, C.F. et al. / Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Yn: The Lancet. 2007 ; Cyfrol 369, Rhif 9561. tt. 559-570.

RIS

TY - JOUR

T1 - Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

AU - Coombes, R.C.

AU - Kilburn, L.S.

AU - Snowdon, C.F.

AU - Paridaens, R.

AU - Coleman, R.E.

AU - Jones, S.E.

AU - Jassem, J.

AU - Van de Velde, C.J.

AU - Delozier, T.

AU - Alvarez, I.

AU - Del Mastro, L.

AU - Ortmann, O.

AU - Diedrich, K.

AU - Coates, A.S.

AU - Bajetta, E.

AU - Holmberg, S.B.

AU - Dodwell, D.

AU - Mickiewicz, E.

AU - Andersen, J.

AU - Lonning, P.E.

AU - Coccini, G.

AU - Forbes, J.

AU - Castiglione, M.

AU - Stuart, N.S.

AU - Stewart, A.

AU - Fallowfield, L.J.

AU - Bertelli, G.

AU - Hall, E.

AU - Bogle, R.G.

AU - Carpentieri, M.

AU - Colajori, E.

AU - Subar, M.

AU - Ireland, E.

AU - Bliss, J.M.

PY - 2007/2/1

Y1 - 2007/2/1

KW - MEDICINE

KW - GENERAL & INTERNAL

U2 - 10.1016/S0140-6736(07)60200-1

DO - 10.1016/S0140-6736(07)60200-1

M3 - Article

VL - 369

SP - 559

EP - 570

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9561

ER -